Evaluation of vitamin D deficiency treatment in patients with calcium kidney stones

Comparative study of the effects of hypovitaminosis D treatment with loading and maintenance methods on serum vitamin D status, 24-hour urine calcium, and serum and urine oxidative stress status in patients with calcium kidney stones

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160206026406N4

Enrollment

Registered

2019-08-13

Start date

2018-07-28

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Recurrent calcium stone formers. Condition 2: Vitamin D deficiency. Calculus of kidney Vitamin D deficiency

Interventions

Intervention 1: Intervention group 1: This group receives vitamin D with a dose of 50000 IU weekly for 8 weeks. Intervention 2: Intervention group 2: The group receives vitamin D with a dose of 2000

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Serum vitamin D 10-20 ng/ml body mass index under 30 Willingness to cooperate in the study

Exclusion criteria

Exclusion criteria: Known Cystine or Struvite kidney stones Hypercalcemia 24-Hour urine calcium higher than 300 mg / 24h Stone pass or gross hematuria in the last 2 months New prescription or changing the dose of thiazide drugs or any drug that has an effect on calcium metabolism Taking antiepileptic or glucocorticoid drugs or any medication that has an effect on vitamin D absorption. Any history of the following diseases: hepatic diseases, diabetes mellitus, thyroid diseases, hyperparathyroidism, immunological diseases, cancers, chronic diarrhea, chronic kidney diseases, urinary tract infection, fat malabsorption, celiac disease, cystic fibrosis. Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
24-hour urine calcium level. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;Serum vitamin D. Timepoint: Before the intervention and 3 months later. Method of measurement: ELISA.;Serum and urine Malondialdehyde. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;Serum and urine total antioxidant capacity. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.	—

Measure

Time frame

24-hour urine calcium level. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;Serum vitamin D. Timepoint: Before the intervention and 3 months later. Method of measurement: ELISA.;Serum and urine Malondialdehyde. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;Serum and urine total antioxidant capacity. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.

—

Secondary

Measure	Time frame
Serum PTH level. Timepoint: Before the intervention and 3 months later. Method of measurement: ELISA.;Serum calcium. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;24 hour urine creatinine. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;24 hour urine urea. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;24 hour urine sodium. Timepoint: Before the intervention and 3 months later. Method of measurement: Ion-selective electrode potentiometry (ISE).;Calcium oxalate supersaturation. Timepoint: Before the intervention and 3 months later. Method of measurement: Calculated by LITHORISK software.;Calcium phosphate supersaturation. Timepoint: Before the intervention and 3 months later. Method of measurement: Calculated by LITHORISK software.	—

Measure

Time frame

Serum PTH level. Timepoint: Before the intervention and 3 months later. Method of measurement: ELISA.;Serum calcium. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;24 hour urine creatinine. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;24 hour urine urea. Timepoint: Before the intervention and 3 months later. Method of measurement: Colorimetry.;24 hour urine sodium. Timepoint: Before the intervention and 3 months later. Method of measurement: Ion-selective electrode potentiometry (ISE).;Calcium oxalate supersaturation. Timepoint: Before the intervention and 3 months later. Method of measurement: Calculated by LITHORISK software.;Calcium phosphate supersaturation. Timepoint: Before the intervention and 3 months later. Method of measurement: Calculated by LITHORISK software.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLilit Sardari Masihi

Tehran University of Medical Sciences

lilitsardari@gmail.com+98 21 8895 5975

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026